Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA REGIONAL OFFICE CONSOLIDATION

Executive Summary

FDA REGIONAL OFFICE CONSOLIDATION involves closing four of the 10 existing offices and incorporating the 40 affected regional office personnel into their respective district offices. The move, which becomes effective in October 1988, calls for closing offices in Boston, Kansas City, Denver and Seattle. In a July 7 "Talk Paper" announcing the change, FDA said that the effort to "streamline FDA's field operations" was "one of the last major goals of Action Plan Phase I." According to Office of Regulatory Affairs officials, the reduced regional offices will not impact the activities of district offices. Under the plan, regional boundaries will be redrawn and the new regions will be renamed. Descriptive geographic names will replace the present numerical designations. The consolidation follows the recent retirement of the four regional directors in charge of the closing offices. FDA noted that with 10 regional offices, some of the offices only had responsibility for overseeing one of FDA's 21 district groups. Under the six-region system, each regional office will have responsibility for at least three district offices. FDA Commissioner Young commented that "the restructuring will enhance the level of service and protection that FDA offers the public because it will make more effective use of FDA resources." FDA NEW REGIONAL OFFICES The following table lists FDA's six new regional offices by name, the location of the field office and the territories covered. NORTHEAST (New York City): Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut and New York State MID-ATLANTIC (Philadelphia): Pennsylvania, New Jersey, Delaware, Maryland, Virginia, West Virginia, Ohio and Kentucky SOUTHEAST (Atlanta): North Carolina, South Carolina, Tennessee, Georgia, Florida, Alabama, Mississippi, Louisiana and Puerto Rico MIDWEST (Chicago): Michigan, Indiana, Illinois, Wisconsin, Minnesota, North Dakota and South Dakota SOUTHWEST (Dallas): Texas, Arkansas, Oklahoma, Missouri, Kansas, Iowa, Nebraska, New Mexico, Colorado, Utah and Wyoming PACIFIC (San Francisco): Alaska, Hawaii, Arizona, California, Nevada, Idaho, Montana, Oregon and Washington

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS012188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel